VNDA FY 2019 Earnings Report — Vanda Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

Vanda Pharmaceuticals Inc.VNDA

FY 2019 Earnings

Reported February 26, 2020

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2019	Prior Q	FY 2018	QoQ Change	YoY Change
Revenue	$227M	—	$193M	—	17.6%
Op. Income	$23M	—	$22M	—	4.9%
Gross Margin	89.2%	—	89.4%	—	-0.2pp
Net Margin	50.9%	—	13.1%	—	37.8pp
EPS (Diluted)	$2.11	—	$0.48	—	339.6%
Free Cash Flow	$45M	—	$5M	—	872.9%

Revenue Flow

Item	Amount
REVENUE	$227M
Cost of Revenue	$24M
GROSS PROFIT	$203M
R&D Expenses	$49M
Selling & Marketing	$3M
General & Administrative	$127M
SG&A Expenses	$130M
Other Expenses	$2M
Operating Expenses	$180M
Cost & Expenses	$204M
OPERATING INCOME	$23M
Interest Income	$6M
Interest Expense	$0
Other Income/Expenses	$6M
INCOME BEFORE TAX	$29M
Income Tax Expense	-$87M
Net Income from Continuing Ops	$116M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$116M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$116M
D&A	$3M
EBIT	$23M
EBITDA	$26M
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$227M
Cost of Revenue	$24M
GROSS PROFIT	$203M
R&D Expenses	$49M
Selling & Marketing	$3M
General & Administrative	$127M
SG&A Expenses	$130M
Other Expenses	$2M
Operating Expenses	$180M
Cost & Expenses	$204M
OPERATING INCOME	$23M
Interest Income	$6M
Interest Expense	$0
Other Income/Expenses	$6M
INCOME BEFORE TAX	$29M
Income Tax Expense	-$87M
Net Income from Continuing Ops	$116M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$116M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$116M
D&A	$3M
EBIT	$23M
EBITDA	$26M
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$116M
Depreciation & Amortization	$3M
Stock-Based Compensation	$0
Deferred Income Tax	-$88M
Other Non-Cash Items	$12M
Change in Working Capital	$3M
OPERATING CASH FLOW	$46M
Capital Expenditure	-$1M
Acquisitions (Net)	$0
Purchases of Investments	-$395M
Sales/Maturities of Investments	$327M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$68M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$6M
FREE CASH FLOW	$45M
Net Change in Cash	-$16M

Balance Sheet

Item	Amount
Cash & Equivalents	$45M
Short-Term Investments	$267M
Net Receivables	$26M
Inventory	$1M
Other Current Assets	$15M
TOTAL CURRENT ASSETS	$354M
PP&E (Net)	$15M
Goodwill	$0
Intangible Assets	$23M
Long-Term Investments	$578.0K
Tax Assets	$88M
Other Non-Current Assets	$3M
TOTAL NON-CURRENT ASSETS	$130M
TOTAL ASSETS	$484M
Account Payables	$6M
Short-Term Debt	$2M
Deferred Revenue	$0
Other Current Liabilities	$45M
TOTAL CURRENT LIABILITIES	$60M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$843.0K
TOTAL NON-CURRENT LIABILITIES	$13M
TOTAL LIABILITIES	$73M
Common Stock	$54.0K
Additional Paid-In Capital	$631M
Retained Earnings	-$221M
Treasury Stock	$0
Accum. Other Comp. Income	$249.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$411M
Minority Interest	$0
TOTAL EQUITY	$411M
TOTAL LIABILITIES & EQUITY	$484M
Total Debt	$15M
Net Debt	-$30M